a | The examination of molecular phenotypes, such as transcript levels, in genetically randomized mouse or human populations is a powerful strategy to identify molecular networks underlying complex traits. For example, genetic variations perturb both the molecular phenotypes (transcript levels) and clinical traits. Loci controlling transcript levels (termed expression QTLs, eQTLs) can be mapped and used to prioritize positional candidates111. Genes that vary together when subjected to multiple genetic perturbations are likely to share regulatory pathways, and the relationships thus obtained often closely parallel known biology, and have in some cases been validated by experimental perturbations (for example, REFS 83, 107, 111). b | A co-expression network of about 3,000 genes constructed from liver gene expression patterns of a segregating population of mice identifies modules of highly correlated genes133, which are indicated by the different colours. As some modules are highly correlated with clinical traits, they can explain much more of the total variation than any individual locus. Although it is possible that modules are due to the perturbing effects of the clinical traits themselves, this is unlikely because there is little overlap between the loci controlling the clinical traits and the loci perturbing the module genes. c | Correlations of the individual colour-coded liver modules from part b (correlations averaged over their genes) and body weight133. Strong correlation of particular network modules (for example, the module marked with an asterisk) with clinical traits provides a means of identifying new disease pathways. Although co-expression networks do not indicate the direction of interaction between nodes, causal modelling can be performed as discussed in BOX 5 to create ‘directed networks’. d | Sub-section of predicted causal interactions involving sortilin 1 (SORT1) and other genes in the liver30. Part d is reproduced from REF. 30.